MedTrace Logo

Prevention of Colorectal Cancer Through Multiomics Blood Testing

NCT04369053 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48995

Last updated 2025-12-26

Study results available
· View outcomes & findings →

Summary

The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.

Conditions

Interventions

DIAGNOSTIC_TEST

Freenome test

Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.

Sponsors & Collaborators

  • Freenome Holdings Inc.

    lead INDUSTRY

Principal Investigators

  • Aasma Shaukat, MD, MPH · NYU Langone Health

  • Theodore R Levin, MD · Kaiser Permanente Division of Research

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04369053 on ClinicalTrials.gov